Hereditary Transthyretin Amyloidosis Global Market Report 2025

Name: Hereditary Transthyretin Amyloidosis Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Download Sample Buy Report

Global Hereditary Transthyretin Amyloidosis Market Report 2025

Hereditary Transthyretin Amyloidosis Global Market Report 2025 - By Type (Oral, Subcutaneous Injection, Other Types), By Drug Class (RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Application (Hospital, Clinic, Other Applications) - Market Size, Trends, And Global Forecast 2025-2034

Hereditary Transthyretin Amyloidosis Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : April 2025 | Delivery Time: 2-3 business days Info | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Hereditary Transthyretin Amyloidosis Global Market Report 2025

Proud Members Of

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Hereditary Transthyretin Amyloidosis Market?

Hereditary transthyretin amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in organs. This condition primarily affects the nervous system, heart, and other tissues, causing progressive neuropathy and cardiomyopathy.

The main types of hereditary transthyretin amyloidosis are oral, subcutaneous injection, and other types. Oral administration, involving tablets, capsules, or liquids, offers a convenient and patient-friendly treatment option for hATTR amyloidosis, improving accessibility and adherence. The drug classes used in the treatment of hATTR amyloidosis include RNAi agents, such as patisiran, and small interfering RNAs (siRNAs) like vutrisiran. These therapies are distributed through hospital pharmacies and retail pharmacies and used in applications such as hospitals, clinics, and others.

Hereditary Transthyretin Amyloidosis Market Size and growth rate 2025 to 2029: Graph

What Is The Hereditary Transthyretin Amyloidosis Market Size 2025 And Growth Rate?

The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the rising incidence of this disorder, an increase in research and development activities, an increasing number of cardiac amyloidosis cases, growing disease awareness, and increasing healthcare infrastructure.

What Is The Hereditary Transthyretin Amyloidosis Market Growth Forecast?

The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to a growing geriatric population, rising disposable incomes, increasing incidence of hereditary transthyretin amyloidosis, a rise in the development of new drugs, and a rise in genetic testing. Major trends in the forecast period include advanced treatment products, advancements in diagnostic techniques, advancements in drug development, demand for effective therapies, and advancements in medical technology.

Book your 30 minutes free consultation with our research experts

How Is The Hereditary Transthyretin Amyloidosis Market Segmented?

The hereditary transthyretin amyloidosis market covered in this report is segmented –

1) By Type: Oral, Subcutaneous Injection, Other Types

2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies

4) By Application: Hospital, Clinic, Other Applications

Subsegments:

1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies

2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran

3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies

What Is Driving The Hereditary Transthyretin Amyloidosis Market? Rising Geriatric Population Driving The Growth Of The Market Due To Increasing Disease Prevalence

The growing geriatric population is expected to propel the growth of the hereditary transthyretin amyloidosis market going forward. The geriatric population refers to individuals aged 65 and older, often requiring specialized healthcare and support due to aging. The geriatric population is growing due to increasing life expectancy driven by advancements in healthcare and living conditions. Hereditary transthyretin amyloidosis (hATTR) significantly impacts the geriatric population by causing progressive neuropathy and cardiomyopathy, leading to increased morbidity in aging individuals. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the growing geriatric population is driving the growth of the hereditary transthyretin amyloidosis market.

Who Are The Major Players In The Global Hereditary Transthyretin Amyloidosis Market?

Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.

What Are The Key Trends Of The Global Hereditary Transthyretin Amyloidosis Market? Innovative RNAi Therapeutics Driving Advancements In The Market

Major companies operating in the hereditary transthyretin amyloidosis market are developing innovative therapeutics, such as RNAi therapeutics, to target and reduce the production of transthyretin (TTR) protein. RNAi therapeutics are a class of drugs that use RNA interference technology to silence specific genes, thereby reducing the production of disease-causing proteins. For instance, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) as a treatment for transthyretin amyloidosis with cardiomyopathy. This submission underscores its innovative RNAi therapeutic approach, designed to target and reduce transthyretin (TTR) protein, a key factor in disease progression. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, positioning it as a potentially transformative option for individuals with this serious condition.

What Are Latest Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market? Ionis Pharmaceuticals And Astrazeneca Partner To Develop Eplontersen For ATTR

In July 2023, Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company specializing in RNA-targeted drug discovery and development, partnered with AstraZeneca plc to jointly develop and market eplontersen for the treatment of transthyretin amyloidosis (ATTR) in the U.S. This collaboration also seeks to expand global access to the treatment by leveraging AstraZeneca’s strong commercial presence, particularly in Latin America and other international markets. AstraZeneca plc. is a UK-based biopharmaceutical company dedicated to the discovery, development, and commercialization of prescription medicines.

What Is The Regional Outlook For The Global Hereditary Transthyretin Amyloidosis Market?

North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hereditary transthyretin amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hereditary Transthyretin Amyloidosis Market?

The hereditary transthyretin amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and genetic counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary transthyretin amyloidosis market also includes sales of genetic testing kits, imaging technologies, biomarkers, and assays. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Hereditary Transthyretin Amyloidosis Industry?

The hereditary transthyretin amyloidosis market research report is one of a series of new reports from The Business Research Company that provides hereditary transthyretin amyloidosis market statistics, including the hereditary transthyretin amyloidosis industry global market size, regional shares, competitors with the hereditary transthyretin amyloidosis market share, detailed hereditary transthyretin amyloidosis market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary transthyretin amyloidosis industry. This hereditary transthyretin amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Hereditary Transthyretin Amyloidosis Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.50 billion
Revenue Forecast In 2034	$2.14 billion
Growth Rate	CAGR of 9.4% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The hereditary transthyretin amyloidosis market covered in this report is segmented – 1) By Type: Oral, Subcutaneous Injection, Other Types 2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran) 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies 4) By Application: Hospital, Clinic, Other Applications Subsegments: 1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies 2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran 3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Hereditary Transthyretin Amyloidosis Market Characteristics

3. Hereditary Transthyretin Amyloidosis Market Trends And Strategies

4. Hereditary Transthyretin Amyloidosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Hereditary Transthyretin Amyloidosis Growth Analysis And Strategic Analysis Framework

5.1. Global Hereditary Transthyretin Amyloidosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Hereditary Transthyretin Amyloidosis Market Growth Rate Analysis

5.4. Global Hereditary Transthyretin Amyloidosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Hereditary Transthyretin Amyloidosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Hereditary Transthyretin Amyloidosis Total Addressable Market (TAM)

6. Hereditary Transthyretin Amyloidosis Market Segmentation

6.1. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Subcutaneous Injection

Other Types

6.2. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

RNAi Agents (Patisiran)

Small Interfering RNAs (siRNAs) (Vutrisiran)

6.3. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

6.4. Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital

Clinic

Other Applications

6.5. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tafamidis

Diflunisal

Experimental Oral Therapies

6.6. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Patisiran

Inotersen

Vutrisiran

6.7. Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous Therapies

Gene Silencing Therapies

CRISPR-Based Therapies

7. Hereditary Transthyretin Amyloidosis Market Regional And Country Analysis

7.1. Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Transthyretin Amyloidosis Market

8.1. Asia-Pacific Hereditary Transthyretin Amyloidosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Transthyretin Amyloidosis Market

9.1. China Hereditary Transthyretin Amyloidosis Market Overview

9.2. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Transthyretin Amyloidosis Market

10.1. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Transthyretin Amyloidosis Market

11.1. Japan Hereditary Transthyretin Amyloidosis Market Overview

11.2. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Transthyretin Amyloidosis Market

12.1. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Transthyretin Amyloidosis Market

13.1. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Transthyretin Amyloidosis Market

14.1. South Korea Hereditary Transthyretin Amyloidosis Market Overview

14.2. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Transthyretin Amyloidosis Market

15.1. Western Europe Hereditary Transthyretin Amyloidosis Market Overview

15.2. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Transthyretin Amyloidosis Market

16.1. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Transthyretin Amyloidosis Market

17.1. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Transthyretin Amyloidosis Market

18.1. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Transthyretin Amyloidosis Market

19.1. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Transthyretin Amyloidosis Market

20.1. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Transthyretin Amyloidosis Market

21.1. Eastern Europe Hereditary Transthyretin Amyloidosis Market Overview

21.2. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Transthyretin Amyloidosis Market

22.1. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Transthyretin Amyloidosis Market

23.1. North America Hereditary Transthyretin Amyloidosis Market Overview

23.2. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Transthyretin Amyloidosis Market

24.1. USA Hereditary Transthyretin Amyloidosis Market Overview

24.2. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Transthyretin Amyloidosis Market

25.1. Canada Hereditary Transthyretin Amyloidosis Market Overview

25.2. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Transthyretin Amyloidosis Market

26.1. South America Hereditary Transthyretin Amyloidosis Market Overview

26.2. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Transthyretin Amyloidosis Market

27.1. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Transthyretin Amyloidosis Market

28.1. Middle East Hereditary Transthyretin Amyloidosis Market Overview

28.2. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Transthyretin Amyloidosis Market

29.1. Africa Hereditary Transthyretin Amyloidosis Market Overview

29.2. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Transthyretin Amyloidosis Market Competitive Landscape And Company Profiles

30.1. Hereditary Transthyretin Amyloidosis Market Competitive Landscape

30.2. Hereditary Transthyretin Amyloidosis Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Novo Nordisk Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Transthyretin Amyloidosis Market Other Major And Innovative Companies

31.1. Regeneron Pharmaceuticals Inc.

31.2. Alexion Pharmaceuticals Inc.

31.3. Alnylam Pharmaceuticals Inc.

31.4. PTC Therapeutics Inc.

31.5. Ionis Pharmaceuticals Inc.

31.6. BridgeBio Pharma Inc.

31.7. Akcea Therapeutics

31.8. Prothena Corporation plc

31.9. Intellia Therapeutics Inc.

31.10. YoITech Therapeutics

31.11. Corino Therapeutics Inc.

31.12. Attralus Inc.

31.13. BSIM Therapeutics SA

31.14. Eidos Therapeutics

31.15. Autotac Bio Inc

32. Global Hereditary Transthyretin Amyloidosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market

34. Recent Developments In The Hereditary Transthyretin Amyloidosis Market

35. Hereditary Transthyretin Amyloidosis Market High Potential Countries, Segments and Strategies

35.1 Hereditary Transthyretin Amyloidosis Market In 2029 - Countries Offering Most New Opportunities

35.2 Hereditary Transthyretin Amyloidosis Market In 2029 - Segments Offering Most New Opportunities

35.3 Hereditary Transthyretin Amyloidosis Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Pfizer Inc. Financial Performance

Table 79: AbbVie Inc. Financial Performance

Table 80: Sanofi S.A. Financial Performance

Table 81: AstraZeneca plc Financial Performance

Table 82: Novo Nordisk Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Hereditary Transthyretin Amyloidosis Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Subcutaneous Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Hereditary Transthyretin Amyloidosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Hereditary Transthyretin Amyloidosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Hereditary Transthyretin Amyloidosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Hereditary Transthyretin Amyloidosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Pfizer Inc. Financial Performance

Figure 79: AbbVie Inc. Financial Performance

Figure 80: Sanofi S.A. Financial Performance

Figure 81: AstraZeneca plc Financial Performance

Figure 82: Novo Nordisk Financial Performance

How is the Allergy Diagnostics Market Poised for Growth: Trends and Opportunities Through 2034

Future Outlook of the Ambulatory Electronic Medical Records Market: Growth, Trends, and Emerging Opportunities Explored

Antimicrobial Susceptibility Testing Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

Assisted Reproductive Technology Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

How is the Bed Monitoring System & Baby Monitoring System Market Poised for Growth: Trends and Opportunities Through 2034

Growth Opportunities and Trends in the Biopharmaceutical CMO Market: Key Insights for 2025-2034

How Will the Bipolar Disorder Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond

Key Trends and Insights into the Bleeding Disorders Treatment Market: Growth Rate and Opportunities to 2034

Hereditary Cancer Testing Global Market Report 2025 – By Test Type( Multi Panel Test, Single-site Genetic Test), By Indication( Breast Cancer, Ovarian Cancer, Colorectal Cancer, Other Indications), By End user( Hospital, Clinics, Diagnostic Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hereditary Angioedema Therapeutics Global Market Report 2025 – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-demand) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Testing, Magnetic Resonance Imaging (MRI), Mammography, Other Diagnosis), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Prosthetic Heart Valve Devices And Equipment Global Market Report 2025 – By Product Type (Repair Products, Mitral Valve Repair Devices, Tricuspid Valve Repair Devices), By Type (Transcatheter Heart Valve, Tissue Heart Valve, Mechanical Heart Valve), By Technology (Biological Valve, Decellularized Valve), By Application (Hospitals, Ambulatory Surgery Centres) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hearth Global Market Report 2025 – By Product (Fireplace, Stove, Insert), By Fuel Type (Gas, Electricity, Wood, Pellet), By Design (Traditional, Modern), By Placement (Indoor, Outdoor, Portable), By Application (Commercial, Residential, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Flea, Tick, And Heartworm Products Global Market Report 2025 – By Product (Spray, Oral Pills or Chewable, Powder, Spot On, Shampoo, Other Products), By Animal Type (Canine, Feline, Other Animal Types), By Distribution Channel (Veterinary Clinics, Retail, E-commerce) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Heart Attack Diagnostic Global Market Report 2025 – By Test Type( Electrocardiogram (ECG/EKG), Blood Tests, X-Ray, Echocardiogram, Coronary Catheterization (Angiogram), Exercise Stress Test, Magnetic Resonance Imaging (MRI)), By Procedure( Invasive Procedure, Non-Invasive Procedure), By End-Use Industry( Hospitals, Ambulatory Surgical Centers, Diagnostics Centers, Other End-Users ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Implantable Heart Pacemaker Global Market Report 2025 – By Product Type( Single Chamber, Dual Chamber, Biventricular), By Application( Heart Block, Sick Sinus Syndrome, Diagnosing Heart Diseases, Other Applications), By End User( Hospital, Clinics, House Hold, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Hereditary Transthyretin Amyloidosis market?

How will the Hereditary Transthyretin Amyloidosis market drivers and restraints affect the market dynamics? What forces will shape the Hereditary Transthyretin Amyloidosis industry going forward?

The Hereditary Transthyretin Amyloidosis market major growth driver - Rising Geriatric Population Driving The Growth Of The Market Due To Increasing Disease Prevalence. For further insights on the Hereditary Transthyretin Amyloidosis market, request a sample here

What is the forecast market size or the forecast market value of the Hereditary Transthyretin Amyloidosis market?

The Hereditary Transthyretin Amyloidosis market size has grown strongly in recent years. The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the rising incidence of this disorder, an increase in research and development activities, an increasing number of cardiac amyloidosis cases, growing disease awareness, and increasing healthcare infrastructure. The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to a growing geriatric population, rising disposable incomes, increasing incidence of hereditary transthyretin amyloidosis, a rise in the development of new drugs, and a rise in genetic testing. Major trends in the forecast period include advanced treatment products, advancements in diagnostic techniques, advancements in drug development, demand for effective therapies, and advancements in medical technology. For further insights on the Hereditary Transthyretin Amyloidosis market, request a sample here

How is the Hereditary Transthyretin Amyloidosis market segmented?

The Hereditary Transthyretin Amyloidosis market covered in this report is segmented –
1) By Type: Oral; Subcutaneous Injection; Other Types
2) By Drug Class: RNAi Agents (Patisiran); Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By Application: Hospital; Clinic; Other Applications

Subsegments:
1) By Oral: Tafamidis; Diflunisal; Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran; Inotersen; Vutrisiran
3) By Other Types: Intravenous Therapies; Gene Silencing Therapies; CRISPR-Based Therapies For further insights on the Hereditary Transthyretin Amyloidosis market, request a sample here

Which region has the largest share of the Hereditary Transthyretin Amyloidosis market? What are the other regions covered in the report?

Who are the major players in the Hereditary Transthyretin Amyloidosis market?

What are the key trends in the Hereditary Transthyretin Amyloidosis market?

Major trends in the Hereditary Transthyretin Amyloidosis market include Innovative RNAi Therapeutics Driving Advancements In The Market. For further insights on the Hereditary Transthyretin Amyloidosis market, request a sample here.

What are the major opportunities in the Hereditary Transthyretin Amyloidosis market? What are the strategies for the Hereditary Transthyretin Amyloidosis market?

For detailed insights on the major opportunities and strategies in the Hereditary Transthyretin Amyloidosis market, request a sample here.

How does the Hereditary Transthyretin Amyloidosis market relate to the overall economy and other similar markets?

For detailed insights on Hereditary Transthyretin Amyloidosis's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Hereditary Transthyretin Amyloidosis industry?

For detailed insights on the mergers and acquisitions in the Hereditary Transthyretin Amyloidosis industry, request a sample here.

What are the key dynamics influencing the Hereditary Transthyretin Amyloidosis market growth? SWOT analysis of the Hereditary Transthyretin Amyloidosis market.

For detailed insights on the key dynamics influencing the Hereditary Transthyretin Amyloidosis market growth and SWOT analysis of the Hereditary Transthyretin Amyloidosis industry, request a sample here.

Hereditary Transthyretin Amyloidosis Global Market Report 2025

Hereditary Transthyretin Amyloidosis Global Market Report 2025

Market Insights

Related Reports

What Is Covered Under Hereditary Transthyretin Amyloidosis Market?

What Is The Hereditary Transthyretin Amyloidosis Market Size 2025 And Growth Rate?

What Is The Hereditary Transthyretin Amyloidosis Market Growth Forecast?

How Is The Hereditary Transthyretin Amyloidosis Market Segmented?

What Is Driving The Hereditary Transthyretin Amyloidosis Market? Rising Geriatric Population Driving The Growth Of The Market Due To Increasing Disease Prevalence

Who Are The Major Players In The Global Hereditary Transthyretin Amyloidosis Market?

What Are The Key Trends Of The Global Hereditary Transthyretin Amyloidosis Market? Innovative RNAi Therapeutics Driving Advancements In The Market

What Are Latest Mergers And Acquisitions In The Hereditary Transthyretin Amyloidosis Market? Ionis Pharmaceuticals And Astrazeneca Partner To Develop Eplontersen For ATTR

What Is The Regional Outlook For The Global Hereditary Transthyretin Amyloidosis Market?

What Defines the Hereditary Transthyretin Amyloidosis Market?

How is Market Value Defined and Measured?

What is the Market Assessment and Strategic Outlook for the Hereditary Transthyretin Amyloidosis Industry?

Table Of Contents

List Of Tables

List Of Figures

How is the Allergy Diagnostics Market Poised for Growth: Trends and Opportunities Through 2034

Future Outlook of the Ambulatory Electronic Medical Records Market: Growth, Trends, and Emerging Opportunities Explored

Antimicrobial Susceptibility Testing Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

Assisted Reproductive Technology Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

How is the Bed Monitoring System & Baby Monitoring System Market Poised for Growth: Trends and Opportunities Through 2034

Growth Opportunities and Trends in the Biopharmaceutical CMO Market: Key Insights for 2025-2034

How Will the Bipolar Disorder Therapeutics Market Grow? Key Trends and Opportunities for 2025 and Beyond

Key Trends and Insights into the Bleeding Disorders Treatment Market: Growth Rate and Opportunities to 2034

Frequently Asked Questions